<DOC>
	<DOCNO>NCT02529605</DOCNO>
	<brief_summary>This single dose , randomize , cross-over pharmacokinetic study healthy volunteer ( n=12 ) two dietary supplement formulation . The Product B® IsaGenesis® formulation represent new reformulation exist product know simply IsaGenesis® . Beyond change relative abundance constituent earlier IsaGenesis® formulation , Product B® IsaGenesis® product formulate liquid-gel formulation ( rather dry powder extract ) theorize enhance absorption bioavailability contain botanical constituent . The purpose study compare two dietary supplement formulation relative absorption two compound contain within supplement know flavonolignans silybin A silybin B bloodstream oral administration capsule .</brief_summary>
	<brief_title>Relative Bioavailability Two Different Milk Thistle Formulations</brief_title>
	<detailed_description>The study involve total five ( 5 ) visit University Florida Shands CRC locate Clinical Translational Research Building Gainesville , expect last approximately 6 week . Screening / Informed Consent : The Screening Visit conduct CRC expect last approximately 1 hour . After obtain write Informed Consent , study subject interview medical history protocol 's Inclusion/Exclusion criterion discuss . All potential participant must nonsmoker , take prescription over-the-counter medication botanical/nutritional supplement ( inclusive vitamin ) . Additionally , participant request abstain alcohol use 24 hour prior study health screen lab work schedule study visit participate fully study . During initial visit , interested subject blood sample draw health screening purpose include baseline serum chemistry , complete blood count , urinalysis , urine pregnancy test ( woman ) precede subsequently schedule physical exam possible study participation . Copies laboratory result make available study subject request . Lastly , 12-lead electrocardiogram obtain . Study Visits The following section describes study procedure two major study visit CRC follow Informed Consent satisfactory medical screening . Following overnight fast ( abstention eat food item 9 pm even prior schedule visit ) , subject arrive CRC morning active Study Days remain approximately 8 hour day . After check , medical supervision , skilled CRC staff place indwell venous catheter subject 's arm facilitate serial blood sampling . Female subject provide urine sample pregnancy test . At approximately 8:00 AM subject administer 2 capsule either Product B® IsaGenesis® ( 2 capsule ; 1280 mg per capsule ) IsaGenesis® ( 2 capsule ; 1070 mg per capsule ) depend randomization sequence assign Investigational Pharmacy Services . Capsules administer 240 ml room temperature water subject ask drink entirety . Subjects remain fasted state 4 additional hour follow administration either formulation eliminate potential effect food absorption . Standard meal serve subject least 4 hour post-dosing . The composition amount food eaten throughout day record . Blood sample collection process do indwell venous catheter facilitate serial blood sampling , total 9 blood sample ( ~10 ml ) take 8-hour period two primary study day . Specific time point blood collection immediately prior dose ( 0 time point ) , either Product B® IsaGenesis® ( 2 capsule ; 1280 mg per capsule ) IsaGenesis® ( 2 capsule ; 1070 mg per capsule ) 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 hour . This single dose assessment Product B® IsaGenesis® ( 2 capsule ; 1280 mg per capsule ) IsaGenesis® ( 2 capsule ; 1070 mg per capsule ) pharmacokinetics conduct two described formulation single dose assessment randomize crossover fashion . Following completion initially product administration sample collection , minimum 7-day wash-out period occur prior schedule subject 's return assessment alternate product ( identical study condition collection time ) . Study Exit Visit The investigator subject return within 7 day complete second study formulation pharmacokinetics assessment `` exit '' follow-up lab work consist basic serum chemistry panel CBC well urinalysis .</detailed_description>
	<criteria>Signed Informed Consent Race ethnicity : restriction Body Mass Index ( BMI ) 18.5 28 kg/m2 ( inclusive ) Satisfactory completion screen medical history , physical exam , laboratory evaluation . Females childbearing potential must negative urine pregnancy test prior enrollment avoid pregnancy study participation . With exception oral contraceptive , subject must take prescription counter medication duration study participation Subjects must ongoing use botanical/nutritional supplement , vitamin , energy drink duration study participation The presence know allergy ragweed related plant Asteraceae/Compositae plant family . Members family include ragweed , chrysanthemum , marigold , daisy , others . Milk thistle may cause allergic reaction people sensitive plant . A history ( within past year ) presence clinically significant cardiovascular , cerebrovascular , renal , hepatic , gastrointestinal , pulmonary , immunological , hematological , endocrine , neurologic disease render subject ineligible study . The presence surgical medical condition ( active chronic ) may interfere drug absorption , distribution , metabolism , excretion include ; Gastric bezoar Swallowing disorder Strictures Fistulas GI obstruction Severe dysphagia Crohn 's disease Diverticulitis A positive urine pregnancy test . Any concomitant prescription medication , overthecounter medication , herbal supplement , vitamin study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>dietary supplement</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>